Phenelzine is an antidepressant drug known to increase the risk of hypertensive crisis when dietary tyramine is not restricted. However, this MAO inhibitor inhibits other enzymes not limited to the nervous system. Here we investigated if its antiadipogenic and antilipogenic effects in cultured adipocytes could contribute to decreased body fat in vivo, without unwanted hypertensive or cardiovascular effects.
Introduction
Phenelzine is an irreversible inhibitor of MAO that is not selective for MAO-A or MAO-B. This drug is approved for the treatment of mood disorders and currently prescribed for atypical depression, bipolar depression and major depressive disorder that is resistant to other antidepressant drugs (Baker et al., 2000; Fava, 2000; Song et al., 2013) . Phenelzine is one of the older irreversible MAO inhibitors (MAOIs) that exhibit distinctive efficacy as antidepressant drugs, but with serious side effects, including hypertensive crisis (Birkenhager et al., 2004) . Indeed, phenelzine severely exaggerates the increase of systolic BP (SBP) provoked by acute ingestion of large amounts of tyramine-rich food. As a consequence, dietary restriction is considered essential for the safe use of such MAOIs, and it is strongly recommended to avoid 'tyramine-rich foods', such as cheeses, wines, beers, sausages and other fermented foods in order to limit the risk of cardiovascular complications during treatment. Tyramine displaces catecholamines from neuronal stores and increases discharge from presynaptic vesicles. As tyramine is a MAO substrate, these effects are exacerbated when its half-life is increased by treatment with MAOIs. This becomes a serious adverse effect leading to a marked increase in noradrenaline levels as this neurotransmitter also is protected from inactivation by MAOIs. For this reason, tyramine is known to be involved in the 'cheese effect', a fatal hypertensive crisis induced by dietary amines in depressive patients treated with irreversible MAOIs (Finberg and Gillman, 2011) . Phenelzine reduced, by 9.9-or 17.3-fold, the amount of tyramine required to increase SBP by ≥30 mm Hg, over baseline values (Goren et al., 2010; Marquet et al., 2012) . However, restriction of dietary tyramine is sufficient to prevent fatal SBP elevations during the therapeutic use of non-selective MAOIs in depressed patients, but such precautions have relegated phenelzine to use as a medication of 'last resort'. Indeed, most of the case reports of this drug are related to its toxicity, occurring when its plasma concentrations reach 1 to 4 mg·L À1 , that is, much higher than the therapeutic values (<0.05 mg·L À1 ). Common features of phenelzine overdose include tachycardia, hypertension, then catecholamine depletion, cardiovascular collapse followed by coma and death (Lichtenwalner et al., 1995; Ngo et al., 2010; Waring and Wallace, 2007) . Our aim, in the experiments described here, was not to further define phenelzine toxicity but to investigate novel actions of this 'old drug' on the basis of the following findings: (i) the degradation of catecholamines or 5-HT by MAO occurs in the blood vessels, heart or other tissues, apart from the brain; (ii) amine oxidases other than MAO are widely distributed in the body and are capable of oxidizing dietary amines. One such oxidase is the copper-containing amine oxidases, more precisely the semicarbazide-sensitive amine oxidase, SSAO (also known as AOC3 or VAP-1; Ramonet et al., 2003) , which is abundant in white adipose tissue (WAT) and sensitive to phenelzine (Carpéné et al., 2008; Carpéné et al., 2011; Song et al., 2013) . Moreover, when oxidizing their substrates, MAO, SSAO and other amine oxidases produce hydrogen peroxide and ROS that generate oxidative stress. Accordingly, sustained activation of cardiac MAO induces cardiomyocyte apoptosis (Bianchi et al., 2005) and chronic blockade of the oxidative stress generated by cardiac MAO has been considered as beneficial, in contrast to the adverse effects mentioned above. Additionally, earlier work had indicated a limitation of lipid accumulation in fat cells upon in vitro (Chiche et al., 2009) or in vivo (Carpéné et al., 2014) treatment with phenelzine. Recently, the neuroprotective action of phenelzine has attracted interest (Song et al., 2013) , and its radical scavenger capacity (Galvani et al., 2008) is now considered to be as important as its inhibition of neurotransmitter degradation (Binda et al., 2011) . Lastly, phenelzine has been described to exert effects besides MAO inhibition, such as binding to the imidazoline I 2 site and interactions with amine transporters or the GABA-ergic system (Alemany et al., 1995; Matveychuk et al., 2014; Yan et al., 2016) .
All these results prompted us to examine new effects of sustained treatment with phenelzine, following the suggestion that this hydrazine derivative could influence lipid accumulation. In the present study, our results have shown that treatment with phenelzine of mice fed a standard diet, reduced body fat content without deleterious effect on glucose handling or the cardiovascular system.
Methods

Animals and treatments
All animal care and experimental procedures complied with the principles established by the Institut National de la Santé et de la Recherche Médicale (INSERM, France), under the permission number C31 55507 and were approved by the Animal Ethics Committee of the unit US006 CREFRE (Centre Régional d'Exploration Fonctionnelle et Ressources Expérimentales, Toulouse, France). Male C57BL/6 mice (Charles River, L'arbresle, France) were housed for at least 2 weeks before experimentation, in the INSERM US006 animal facility at four per cage under 12/12 h light/dark cycle with temperature (20-22°C) and humidity (50-60 %) control. The mice had ad libitum access to water and standard chow (Harlan, France), the consumption of which was determined weekly. The mice were 9 weeks old at the start of the experiment. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) .
The study protocol was not subject to randomization and blinding, although mice were divided into two groups of 12 of equivalent body weight (27.9 ± 1.3 and 27.5 ± 1.6 g) at the start of the protocol. Control mice were without treatment. The treated group received phenelzine sulfate in the drinking water for 12 weeks (phenelzine-treated mice) provided as a 0.028% solution, planned to achieve a daily intake of approximately 30 mg phenelzine kg -1 , corresponding to 2.5 mg·kg À1 in human subjects when using inter-species body surface area normalization (Reagan-Shaw et al., 2008) , that is, twofold to threefold higher than therapeutic doses usually prescribed for antidepressant therapy (45-90 mg·day À1 ). Body composition, assessed by NMR with Echo MRI 100TM device (Echo Medical Systems, Houston, USA), and cardiovascular parameters were noninvasively checked, at weeks 9 and 12. Non-fasting blood glucose was determined weekly between 15:00 and 16:00h with a glucose monitor (Roche Diagnostic, Mannheim, Germany), using a blood drop withdrawn from the tail. Fourteen additional mice of the same strain bred under similar conditions but devoid of any treatment were used to provide tissues for further exploration of the short-term in vitro effects of phenelzine on adipocytes and on hydrogen peroxide release by tissue homogenates.
BP and ECG analyses
After training sessions, SBP was measured in conscious mice by non-invasive plethysmographic tail-cuff method, using PowerLab 800S apparatus and Chart Software from Phymep (Paris, France). ECGs were recorded at week 12 during 10 min on mice anaesthetized with isoflurane (1.5%) using the devices Animal BioAmps & PowerLab 8/30. ECGs were analysed with Chart Pro software (AD-Instrument, Oxford, UK). Time-domain analysis of heart rate variability (HRV) gave the following parameters: SD of normal RR intervals (SDNN), reflecting the total HRV; square root of the mean of the squares of the successive differences between adjacent RR intervals (RMSSD) and pNN6% (percentage of RR intervals differing by more than 6 ms, reflecting influence of parasympathetic tone on HRV), which is considered in mice to be the equivalent of pNN50 in man (Thireau et al., 2008) . Frequency-domain analysis was performed using fast Fourier transform of low frequencies (LF, 0.15-1.5 Hz) and high frequencies (HF, 1.5-5 Hz), according to Thireau et al. (2008) .
Organ weight and composition, oxidative damage, circulating parameters
After 12 weeks of treatment, mice were killed by cervical dislocation after overnight fasting. Organ weighing and sample preparation for plasma, heart, liver and skeletal muscles from the hind leg were performed in a blinded manner. Samples were stored at À80°C until analysis. This was also the case for subcutaneous inguinal white adipose tissue (SCWAT) before determining amine oxidase activity and mRNA abundance, with the exception that a portion of SCWAT from five mice in each group, was immediately used for the determination of hydrogen peroxide release by fresh pieces of tissue, as described below. Brown adipose tissue was dissected from the interscapular area (IBAT) while white fat pads from epididymal (EPIWAT) and retroperitoneal plus perirenal (RPWAT) anatomical locations were pooled to prepare adipocyte suspensions. Organ lipid content was determined according to Dole and Meinertz (1960) . Cardiac aconitase activity was assayed with Bioxytech kit from Oxis Research (Portland, USA) and circulating metabolites were determined as previously described (Carpéné et al., 2014) .
Adipocyte lipolytic and lipogenic activities
EPIWAT and RPWAT were immediately digested by liberase (15 μg·mL À1 , type TM, Roche Diagnostics, Meylan, France)
in Krebs-Ringer buffer containing 15 mM bicarbonate, 10 mM HEPES, 2 mM pyruvate and 3.5% of BSA. Separation, washing and dilution of the buoyant adipocytes were performed in the same buffer without liberase as previously described (Carpéné et al., 2014) , before the functional assays. Lipolytic activity was assessed by glycerol release (Carpéné et al., 2016a) Les et al., 2016) .
Tyramine oxidation and hydrogen peroxide release
The method of Zhou and Panchuk-Voloshina, (1997) using the fluorescent substrate 10-acetyl-3,7 dihydrophenoxazine and HRP, was slightly adapted to measure the release of hydrogen peroxide (H 2 O 2 ) by fresh SCWAT samples (20 mg) and to quantify it as an end-product of amine oxidation by MAO or SSAO (Carpéné et al., 2016b released by thawed SCWAT homogenates in the presence of 0.5 mM tyramine during 30 min was used to measure total amine oxidation. The release detected after preincubation with 0.1 mM pargyline is MAO-resistant while that after 1 mM semicarbazide is SSAO-resistant, as previously shown (Carpéné et al., 2008) . WAT homogenates were distributed in 96-well dark microplates (100 μg protein per well of 200 μL phosphate buffer saline pH 7.5), then incubated at 37°C in the dark and fluorescence readouts (ex/em: 540/590 nm) collected on Fluoroskan Ascent microplate reader (ThermoLabsystems, Vantaa, Finland) as in Carpéné et al. (2016b) . H 2 O 2 release was normalized per gram of fresh SCWAT or per mg protein of thawed homogenate.
Real-time RT-PCR
Total RNA was extracted using RNeasy Mini kit (Qiagen, Courtaboeuf, France) according to the manufacturer's instructions. For cDNA synthesis, RNA was reverse transcribed using Superscript II reverse transcriptase (Life Technologies Corporation, Carlsbad, USA) and random hexamers. Real-time PCR was performed in a Step One Plus system (Applied Biosystems, Warrington, UK), using the Sybr green Master Mix (Eurogentec, Liège, Belgium). Oligonucleotide primers were designed and used as previously reported . Relative gene-expression was calculated using the 2
ΔΔCt method with 18S ribosomal RNA as internal control. Sufficient material for such determinations of mRNA abundance was obtained from SCWAT or hearts from six mice per group.
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Biochemical data are given as mean ± SEM of the indicated number (n) of independent observations and were analysed by Student's t-test except for repeated determinations of blood glucose (ANOVA) and for cardiovascular data, which were analysed after checking values for Gaussian distribution and then compared with either unpaired t-test or Mann-Whitney test. Statistical significance was assumed when P < 0.05. Calculations were made with the software Prism 6 for Mac OS X 6.0.
Materials
Phenelzine sulfate and all other compounds used in these experiments were purchased from Sigma-Aldrich-Merck (Saint Quentin Fallavier, France) unless otherwise stated.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/ BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 (Alexander et al., 2017a,b,c) .
Results
Food and water intake, body mass and adiposity
The growth curve of mice drinking the 0.028% phenelzine solution did not differ from control. The 12-week treatment did not modify final body weight (phenelzine-treated mice 30.2 ± 0.6g; control, 31.3 ± 1.2 g ;n = 12). The cumulated food intake of the phenelzine-treated group was similar to that of control, and daily food consumption was 4.4 ± 0.2 and 4.0 ± 0.3 g per mouse, respectively. The cumulative water consumption over the 12 weeks tended to be lower in the phenelzine-treated group (241 ± 24 mL) than in control (284 ± 41 mL per mouse), without reaching significance ( Figure S1 ). Taking into account the changes in water consumption and body mass throughout the treatment, the daily doses of phenelzine ingested by the mice via the drinking solution varied from 108 to 162 μmol·kg À1 day À1 . The overall mean value of 135 ± 6 μmol of phenelzine kg À1 day À1 , equivalent to 31.6 mg·kg À1 day À1 , was close to our expected intake calculations. The first non-invasive measurement of body composition performed after 9 weeks of treatment revealed a decrease in body fat content. This was confirmed at week 12 ( Figure 1A ). When fat depots were dissected and weighed at the end of the experiment, only SCWAT showed a significant reduction of mass in phenelzine-treated mice ( Figure 1B) . Although the other fat pads did not show significant reduction from their respective control, the total amount of dissected fat depots was lower in the phenelzine-treated group, when expressed as relative to body weight or as absolute weight (phenelzine-treated, 1.56 ± 0.08g and control, 1.88 ± 0.11 g of WAT ; n = 12). There was no change in IBAT mass or colour. Such modest reduction of adiposity (17% lower than control) contrasted with the reduced total body fat content (35% lower) observed by NMR and prompted us to determine if other lipid-accumulating organs were modified. No change in liver or heart weight was observed ( Figure 1C) . However, the lipid composition of skeletal muscle was significantly reduced ( Figure 1D ), indicating that change in lipid content was not limited to SCWAT.
Effects of phenelzine treatment on cardiovascular parameters
We measured the cardiovascular parameters to determine if sustained MAO blockade by phenelzine could provoke a hypertensive reaction and/or cardiovascular dysfunction. The BP of conscious mice was not significantly modified by phenelzine administration (Table 1) . Heart rate was not altered in treated mice when measured under non-invasive conditions as well as under mild anaesthesia. Visual examination of ECGs revealed sinus rhythm and absence of ectopic beats. Further analysis showed that atrioventricular and ventricular conductions, reflected by PR interval and the length of the QRS complex were unaffected (Table 1) .
Time-domain analysis of HRV did not show difference between treated and control, as reflected by unchanged SDNN (Table 2) . Similarly, RMSSD values, reflecting short-term variability remained unchanged. The parameter pNN6% tended to increase in phenelzine-treated mice but was not significantly different from control.
Frequency-domain analysis of HRV did not reveal clearcut difference in LF or in HF power, reflecting sympathetic and parasympathetic activity respectively. However, the resulting LF/HF ratio was modestly increased in phenelzinetreated mice (Table 2) , indicative of a sympathetic dominance. There was no difference in aconitase activity in heart homogenates (20.4 ± 0.4, in control; 17.5 ± 1.2 arbitrary units in treated mice, n = 7), as it was also in liver (6.9 ± 1.3, in control; 6.7 ± 1.0 arbitrary units in treated mice, n = 7), indicating that oxidative stress was not sufficient to inactivate the enzyme. In addition, there was no change in the expression of various subsets of genes encompassing cardiac remodelling, fibrosis or apoptosis pathways (Table S2) .
These observations were consistent with a lack of pressor effect and of serious cardiac dysfunction after 12 weeks of treatment in mice fed a standard rodent chow, which is not tyramine-free as it contains 45 mg tyramine kg -1 (Visentin et al., 2003a) .
Glucose handling and circulating lipids
The effects of chronic phenelzine on lipid and glucose handling was also investigated. While non-fasting blood glucose was equivalent in both groups at the beginning of treatment, all subsequent determinations indicated a reduction in the treated group (Figure 2A ). The overall mean value of non-fasting blood glucose fell from 9.57 ± 0.08 mM in control to 8.77 ± 0.08 mM in phenelzine-treated mice (repeated measures ANOVA, P < 0.05), from a total of 82-100 determinations in each group, since not all blood drops could be successfully collected from the tail vein of restrained mice. As non-fasting blood glucose levels are not sufficiently indicative of the ability to maintain glucose homeostasis, we determined glucose and insulin after an overnight fast, at the end of the treatment. Fasting plasma glucose was not significantly lower in the phenelzine group and insulin was unchanged ( Figure 2B ). Consequently, the use of these parameters for an estimate of insulin resistance index did not indicate any significant improvement (5.94 ± 0.75 and 4.89 ± 0.45 in control and treated respectively). Similarly, circulating lipid levels (free fatty acids and glycerol) remained unaltered after phenelzine treatment ( Figure 2C ).
Effects of chronic phenelzine on lipogenic, lipolytic and anti-lipolytic activities in adipocytes
Lipogenesis was more efficiently stimulated by insulin in control than in phenelzine-treated mice ( Figure 3A ). The insulin-like effect of the combination of benzylamine plus vanadate, reported to be an H 2 O 2 -dependent response elicited via oxidation by amine oxidases (Grès et al., 2012) , was altered after treatment, indicating that either lipogenic capacity or amine oxidase activity was inhibited by phenelzine. The dose-dependent stimulation of lipolysis by the β-adrenoceptor agonist isoprenaline was not altered in adipocytes from phenelzine-treated mice, compared with control, reaching a maximum at 1 μM ( Figure 3B ). Similarly, insulin-dependent inhibition of lipolysis was unaltered ( Figure 3C ). Hydrogen peroxide release, amine oxidase activities and gene expression in SCWAT
As phenelzine exerts ROS scavenging properties (Galvani et al., 2008) , H 2 O 2 production was measured in freshly collected pieces of SCWAT. The spontaneous release of H 2 O 2 by small SCWAT explants only tended to be lower in samples from treated mice than in those from the control group ( Figure 4A ). The addition of 100 μM apocynin decreased H 2 O 2 production in both groups. Phenelzine inhibited H 2 O 2 detection to a greater extent when added in vitro, than after in vivo treatment. The lowest ROS levels were observed in SCWAT from the phenelzine-treated group and further incubated with the hydrazine derivative. Such inhibitory effects were confirmed in 14 homogenates of thawed SCWAT from untreated mice, in which only 66.7 ± 2.6% of the spontaneous H 2 O 2 production was found in the presence of 100 μM phenelzine.
H 2 O 2 is one of the end-products of amine oxidation (Olivieri et al., 2011) , and its production by SCWAT homogenates after incubation with 0.5 mM tyramine was lower, after in vivo phenelzine treatment ( Figure 4B ). Added in vitro, the MAO inhibitor pargyline impaired tyramine-induced H 2 O 2 production in control group only, indicating that MAO activity was already blocked in the phenelzine-treated group. Tyramine oxidation was even more inhibited by semicarbazide in control group, confirming the major contribution of SSAO in tyramine metabolism. Semicarbazide impaired tyramine oxidation in the treated group also, indicating that SSAO was not totally blocked after phenelzine treatment. Tyramine oxidation was abolished in both groups only when MAO and SSAO inhibitors were added together in vitro, confirming that both MAO and SSAO oxidize tyramine in these homogenates. Interestingly, 1 μM phenelzine was as effective as the combination of pargyline and Phenelzine reduces body fat without heart injury semicarbazide ( Figure 4B ). Thus, either when administered in vitro or in vivo, phenelzine inhibited both MAO and SSAO in SCWAT. Then, we assessed the effects of phenelzine treatment on the expression of genes involved in adipocyte lipogenic/ lipolytic pathways. Transcriptional expression of PPAR γ (Pparγ2) and of sterol regulatory element-binding protein-1C (Srebp-1c), two factors involved in lipid biosynthesis/ uptake and adipogenesis, remained unmodified, as it was the case for fatty acid synthase (Fasn), which is induced by SREBP-1C. However, the expression of phosphoenol pyruvate carboxykinase (Pepck) was decreased in phenelzine-treated mice ( Figure 5 ). PEPCK is an enzyme necessary for glycolysis and glyceroneogenesis, improving triacylglycerol synthesis under the control of SREBP-1C (Chakravarty et al., 2001) . Such Pepck down-regulation was in line with limited SCWAT increase. The expression of hormone-sensitive lipase (Hsl), one of the major components of the lipolytic cascade, was not up-regulated by phenelzine treatment. This was consistent with the lack of increase of the products of lipid mobilization, namely, plasma FFA and glycerol. 
Figure 4
Effects of oral administration of phenelzine and in vitro treatment on spontaneous and tyramine-induced hydrogen peroxide release by SCWAT. (A) Hydrogen peroxide release by SCWAT explants incubated at 37°C for 30 min without any addition (no add) or with 100 μM apocynin or phenelzine. Data shown are means ± SEM from five animals. (B) Hydrogen peroxide production by SCWAT homogenates incubated for 30 min with 0.5 mM tyramine alone (no inhib) or in the presence of 100 μM pargyline (+parg), 1 mM semicarbazide (+semi), their combination (+parg +semi), or 1 μM phenelzine (+phnlz). Data shown are means ± SEM of seven homogenates per group. *P < 0.05, significantly different from control; unpaired Student's t-test. #P < 0.05, significant effect of inhibitor; paired Student's t-test.
In vitro effect of phenelzine on lipolytic, anti-lipolytic and lipogenic responses in adipocytes
We further explored whether phenelzine directly affected triacylglycerol turnover in SCWAT adipocytes isolated from an independent, untreated, group of mice. Activation of lipolysis by the β-adrenoceptor agonist, isoprenaline, was unaltered in the presence of increasing doses of phenelzine, except at the concentration of 1 mM, which limited the glycerol release ( Figure 6A ). Similarly, millimolar phenelzine inhibited the lipolytic stimulation by isobutylmethylxanthine (IBMX), suggesting that adrenergic and non-adrenergic mechanisms of lipolysis activations were equally impaired ( Figure 6B ). The anti-lipolytic responses were tested on glycerol release stimulated by 10 nM isoprenaline ( Figure 6B ). The addition of 100 nM insulin partly inhibited isoprenalinepromoted glycerol release and this anti-lipolytic effect was unaltered by the MAOI. However, glycerol release tended to reach the lowest levels when insulin was co-incubated with phenelzine (1 mM), probably resulting from an additive inhibition of isoprenaline action. The anti-lipolytic effect of 1 mM tyramine, already reported to be MAO-dependent (Visentin et al., 2003b) , counteracted isoprenaline activation and was impaired by 1 μM phenelzine, probably as a consequence of MAO blockade. However, at higher concentrations, the inhibitory component of phenelzine prevented the detection of further impairment of the anti-lipolytic effects of tyramine.
Finally, we compared the in vitro anti-lipogenic effect of phenelzine with other MAOIs and hydrazine derivatives. The incorporation of radiolabelled glucose into lipids was increased by insulin in adipocytes of untreated mice (Figure 7 ). Such lipogenic action was impaired by the presence of 1 mM phenelzine, pargyline and hydralazine, all MAOIs. Nevertheless, 1 mM semicarbazide, a hydrazinebased SSAO inhibitor devoid of MAOI activity, was without any effect. This was also the case for the DMSO vehicle Figure 5 Relative mRNA levels in SCWAT. mRNA abundance in phenelzinetreated mice was normalized by 18S-RNA and expressed as percentage of respective control for the following genes: Pparγ2, peroxisome proliferator activated receptorγ-2; Srebp-1c, sterol regulatory element-binding protein-1C; Fasn, fatty acid synthase; Pepck, phosphoenol pyruvate carboxykinase; Hsl, hormonesensitive lipase. Data shown are means ± SEM of six SCWAT per group. *P < 0.05, significantly different from control; unpaired Student's t-test.
Figure 6
Influence of acute co-incubation of phenelzine with adrenergic and non-adrenergic agents on lipolytic and antilipolytic responses of mouse adipocytes. (A) Lipolysis is expressed as percentage of maximally stimulated lipolysis (promoted by 1 μM isoprenaline, increasing glycerol release by 11.0 ± 2.3-fold, from 0.058 ± 0.013 to 0.654 ± 0.118 μmol in 90 min). Negative percentages are indicative of a release lower than baseline, while values >100 indicate a stimulation stronger than that elicited by 1 μM isoprenaline. Increasing doses of the β-adrenoceptor agonist (from 0.1 nM to 10 μM) were tested without (control) or with phenelzine at the indicated concentrations (phnlz). (B) Isobutylmethylxanthine (IBMX 1 mM) was used to stimulate lipolysis in a non-adrenergic manner. The antilipolytic effects of insulin (100 nM) or tyramine (1 mM) were tested against submaximal lipolytic activation by 10 nM isoprenaline (iso). The non-adrenergic regulation of lipolysis were tested without (control) or with phenelzine. Data shown are means ± SEM of seven independent adipocyte preparations from SCWAT of untreated mice. *P < 0.05, significantly different from corresponding control; one-way ANOVA with Bonferroni post hoc test.
used for such high concentration of inhibitors. Lastly, aminoguanidine, an inhibitor of a broad range of enzyme activities including diamine oxidase and NO synthase, but which does not inhibit MAO, did not impair lipogenesis substantially.
Discussion
Phenelzine is indicated for the treatment of depression since it increases neurotransmitter levels and exerts neuroprotective effects. Hence, the drug is now recognized to exert various biological actions on the GABA-ergic system (Lai et al., 1998; Matveychuk et al., 2014 ) and on enzymes not limited to the CNS, such as SSAO (Song et al., 2013) and lysine-specific demethylases (Yan et al., 2016) . Additionally, phenelzine exhibits carbonyl scavenging and anti-atherogenic effects (Galvani et al., 2008) and therefore cannot be considered only as a non-selective MAOI. However, it shares with several MAOIs, the severe food-drug interaction (the cheese reaction) consisting of a potentially fatal rise in BP following ingestion of high amounts of dietary tyramine (in cheese or wine). The goal of our study was to uncover metabolic effects of a drug with potential extra-neuronal actions while ascertaining that, at doses larger than the therapeutic doses recommended for antidepressant application, phenelzine did not induce hypertension or other cardiovascular effects.
First of all, we confirmed that MAO-dependent tyramine oxidation was abolished in mice treated for 12 weeks with phenelzine in their drinking water. Such limitation of tyramine degradation occurred without severe cardiovascular adverse effects in mice fed a pelleted chow that contains 45 mg tyramine kg -1 (Visentin et al., 2003a ) and leads to a daily tyramine intake of approximately 6 mg·kg À1 . No sustained hypertensive reaction was detected in phenelzinetreated mice, and the decreased QT interval previously reported by electrocardiographic studies on phenelzinetreated subjects (Georgotas et al., 1987) was not observed in our study. However, we did detect an increased LF/HF ratio, indicative of an altered cardiac sympathovagal balance. Though modest, this change is consistent with the alterations of BP recovery observed after postural change in patients under phenelzine treatment, which corresponded to an impairment of sympathetically mediated cardiovascular responses with intact vagally mediated changes (Coupland et al., 1995) . Although the relevance of the LF/HF ratio is controversial in cardiovascular medicine (Billman, 2013) , HRV changes are recognized to be associated with greatest risk of cardiovascular injury (Compostella et al., 2014; Kosch et al., 1999) . However, except for an increased LF/HF ratio, the phenelzine-treated mice did not show prominent alterations of cardiac hypertrophy, cardiac oxidative stress or abnormal cardiac remodelling/fibrosis. Thus, the increased availability of ingested tyramine under phenelzine treatment and the increased release of catecholamines were not sufficient to induce a prolonged alteration of BP. This interpretation is consistent with previous studies demonstrating that the combined acute administration of tyramine and phenelzine induces a lower pressor response than phenelzine or iproniazid plus β-phenylethylamine in the anaesthetized rat (Cashin, 1972) . Further, at least 80 mg tyramine kg -1 is required to acutely increase SBP by more than 30 mm Hg in rodents, and this amount is further increased when tyramine is diluted in the diet (Fankhauser et al., 1994) . Lastly, historical, non-selective MAOIs, such as pargyline, exhibit a centrally mediated hypotensive effect (Fuentes et al., 1979) and were prescribed as antihypertensive agents (e.g. hydracarbazine). In the present context, it is relevant that phenelzine is a hydrazine derivative inhibiting both MAO and SSAO, just like the strong vasodilator hydralazine (Lyles et al., 1983) . Accordingly, hypotension has been observed in MAO-A/MAO-B deficient mice (Holschneider et al., 2002) , reproducing the hypotensive effect of chronic MAOIs via altered baroreflex sensitivity (Coupland et al., 1995; Yamada and Yasuhara, 2004) . More recently, a spontaneous increase in cardiac MAO activity was shown to contribute to age-associated cardiovascular diseases (Maggiorani et al., 2017) . All these data may explain why phenelzine treatment had little effect on the cardiovascular system in mice, although it inhibited cardiac MAO activity and subsequent ROS generation. In our study, adipose tissue emerged as another target of phenelzine. The MAO and SSAO activities present in WAT were inhibited by phenelzine treatment, which suppressed tyramine-induced H 2 O 2 release. In vitro, phenelzine was more efficient in inhibiting the spontaneous H 2 O 2 release by SCWAT explants than the NADPH-oxidase inhibitor apocynin. Because apocynin treatment lowers adipose tissue ROS levels and improves diabetes and hyperlipidaemia in obese mice (Furukawa et al., 2004) , our attempt to determine if phenelzine might be beneficial for limiting complications in obesity, was entirely justified. As far as adiposity is concerned, the reduction observed in SCWAT mass in phenelzine-treated mice was in agreement with the previously reported anti-adipogenic and anti-lipogenic responses
Figure 7
In vitro effects of phenelzine and related amine oxidase inhibitors on insulin-stimulated incorporation of glucose into lipids of mouse adipocytes. Insulin (100 nM) was incubated in all conditions, except basal, with adipocytes for 120 min at 37°C in the presence of 1 mM of the indicated inhibitor. Data shown are means ± SEM of seven adipocyte preparations from untreated mice. *P < 0.05, significantly different from vehicle (DMSO 1%); one-way ANOVA with Bonferroni post hoc test.
of adipocytes to phenelzine (Byun et al., 2013; Carpéné et al., 2013; Chiche et al., 2009 ). In our experiments, treated mice exhibited a limited decrease of WAT mass, and their body fat content was reduced without loss of body mass. So far, the clinical use of phenelzine has been associated with body weight gain in depressed patients (Cantu and Korek, 1988; Golwyn and Sevlie, 1999) , as it is the case with other antidepressant drugs (Fava, 2000) . However, it remains unclear whether it is the improvement of mood disorder or the psychotropic drug itself that is involved in the weight gain following antidepressant therapy. In phenelzine-treated mice, a decrease in muscle lipid content also contributed to the decrease in body fat content, indicating that ectopic fat deposition (outside the WAT), known to be deleterious in obesity, was reduced during treatment. This lipid lowering effect of phenelzine was observed without change in calorie intake while only a slight tendency to limit water consumption was observed, probably as a consequence of an aversion for the taste of the drug solution. In fact, phenelzine was not acting as a strong lipo-mobilizing agent as it was not associated with increased plasma glycerol and NEFAs, a sign of exaggerated adipocyte lipolysis, but also of lipotoxicity and insulin resistance (Lee et al., 1994) . The tendency to lower the lipolytic effect of the β-adrenoceptor agonist isoprenaline found in SCWAT adipocytes suggested a desensitization process following increased release of catecholamines. Nevertheless, the lack of change of IBAT morphology after 12 weeks of phenelzine treatment did not indicate that the expected sympathetic system activation was strong enough to recruit brown fat and to promote 'browning' of WAT. In contrast, we observed in vitro that phenelzine impaired lipolytic activation by both adrenergic and non-adrenergic lipolytic agents. Although this acute inhibition was detected at millimolar concentrations only, it cannot be ruled out that a similar impairment could occur under chronic treatment, as phenelzine has been described to impair lipolysis in cultured 3T3 adipocytes when incubated at 100 μM for 48 h (Chiche et al., 2009 ). More importantly, phenelzine impaired the lipogenic action of insulin, but not its anti-lipolytic action, both in vivo and in vitro. A rapid inhibition of the incorporation of glucose into lipids was seen in adipocytes incubated with high doses of molecules that share with phenelzine either a hydrazine or an amine function and the ability to inhibit MAO. These anti-lipogenic properties of chronic phenelzine confirmed our previous observations on the influence of the hydrazine derivative on fat cells (Carpéné et al., 2014; Carpéné et al., 2013) and are likely to be involved in the limitation of fat accumulation in the phenelzine-treated mice. Furthermore, the insulin-mimicking effect of benzylamine, which is sensitive to SSAO blockade (Morin et al., 2001) , was also inhibited in phenelzine-treated mice.
In adipocytes, the source of glycerol 3-phosphate required for triacylglycerol synthesis comes largely from glycolysis (glucose) and glyceroneogenesis (pyruvate, lactate), and the kinase PEPCK provides substrates for lipid accumulation. In accordance, the down-regulation of Pepck that we found in WAT, confirmed that de novo assembly of triacylglycerols was decreased. This process likewise applies to the intramyocellular lipid storage in skeletal muscles (Laurens and Moro, 2016) . Inhibition of PEPCK activity by hydrazine sulfate is recognized and decreases gluconeogenesis and blood glucose (Mazzio and Soliman, 2003) . All these actions could explain the hypoglycaemia reported in phenelzine clinical trials (McIntyre et al., 2006) and the lower, non-fasting, blood glucose of mice treated with this hydrazine derivative.
A limitation of the present study is that the lipid lowering action of phenelzine was not tested against an obesogenic challenge. Thus, whether phenelzine administration at higher doses than those therapeutically used to treat depression offers a benefit to obese patients remains to be determined. Meanwhile, we have already reported that phenelzine resulted in a modest reduction of WAT mass in mice exhibiting high fat diet-induced obesity, when testing the putative anti-obesity effect of phenelzine and resveratrol co-administration (Carpéné et al., 2014) . However, it could be of interest to test whether the agent is more active in mitigating the obesity induced by a carbohydrate-rich hypercaloric diet, as the lowering lipid effects of phenelzine appear to deal with reduced incorporation of carbohydrates into lipids rather than an increased mobilization and oxidation of stored lipids. A beneficial use of phenelzine in metabolic disease, if any, should therefore be oriented towards a prevention of excessive lipid accumulation, rather than being considered as a lipid-mobilizing agent. Moreover, future working hypothesis should take into account that, among the adverse effects of this drug, dry mouth could counteract our proposed benefits by increasing the consumption of sweetened beverages (Gunnarsdottir et al., 2010) . In any case, an increased lipotoxicity related to exaggerated lipid mobilization is not expected as we have reported here that phenelzine limited lipolysis, lipogenesis and oxidative stress, without impairing blood glucose handling.
Another limitation of our study is that we have not explored the effects of other MAO inhibitors and other MAO-containing tissues, especially those involved in obesity and hypertension. The perivascular adipose tissue, which has an adrenergic system including MAO, catecholamine transporters and receptors (Ayala-Lopez and Watts, 2017) , is likely to be a target of phenelzine that deserves further investigations as it is intimately connected with the vasculature. Similarly, sympathetic neuron-associated macrophages, the inhibition of which leads to weight loss in obese mice (Pirzgalska et al., 2017) , also express MAO. They are likely to be involved in the changes of catecholamine clearance and sympathetic activity occurring during MAO blockade and are of interest for future studies of the pharmacological mechanisms of phenelzine in mitigating obesity complications.
In conclusion, our observations in WAT, heart, muscles and plasma indicated that phenelzine did not increase the risk of lipotoxicity or cardiovascular disease in mice. The lack of increased lipid mobilization after phenelzine treatment agrees with an expected increase of tyramine content because this compound lacks strong lipolytic effect, in contrast to its derivative N-methyltyramine (Stohs and Hartman, 2015) . Thus, one can expect that phenelzine is not solely blocking MAO in nervous and cardiovascular systems, as it is capable of modulating carbohydrate and lipid metabolism in other tissues by interfering at least with H 2 O 2 metabolism, SSAO and PEPCK activities. Beside their adverse interaction with supranutritional amounts of tyramine, compounds such as phenelzine or other old MAOIs have therefore the potential to mitigate complications of obesity, by improving glucose and lipid handling without increasing the risk of oxidative stress, lipotoxicity or cardiac injury.
